Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001213900-17-012106
Filing Date
2017-11-14
Accepted
2017-11-14 16:40:40
Documents
4
Period of Report
2017-12-20
Effectiveness Date
2017-11-14

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT def14a1217_actiniumpharma.htm DEF 14A 843350
2 GRAPHIC image001.jpg GRAPHIC 28604
3 GRAPHIC image002.jpg GRAPHIC 299368
4 GRAPHIC image003.jpg GRAPHIC 280372
  Complete submission text file 0001213900-17-012106.txt   1662374
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36374 | Film No.: 171202256
SIC: 2834 Pharmaceutical Preparations